Comment on

• When and how to treat acute hepatitis C?

  Licata A, Di Bona D, Schepis F, Shahied L, Craxí A, Cammà C. Licata A, et al. J Hepatol. 2003 Dec;39(6):1056-62. doi: 10.1016/s0168-8278(03)00461-6. J Hepatol. 2003. PMID: 14642626
• Abstracts of the 39th Annual Meeting of the European Association for the Study of the Liver. April 14-18, 2004, Berlin, Germany.

  [No authors listed] [No authors listed] J Hepatol. 2004 Apr;40 Suppl 1:1-197. J Hepatol. 2004. PMID: 15129684 No abstract available.
• Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

  Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Francavilla R, Pastore G. Santantonio T, et al. J Hepatol. 2005 Mar;42(3):329-33. doi: 10.1016/j.jhep.2004.11.021. J Hepatol. 2005. PMID: 15710214 Clinical Trial.
• Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.

  Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F; Swiss Association for the Study of the Liver (SASL 18). Broers B, et al. J Hepatol. 2005 Mar;42(3):323-8. doi: 10.1016/j.jhep.2004.11.018. J Hepatol. 2005. PMID: 15791696 Clinical Trial.